article thumbnail

Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea

Cannabis Law Report

The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. If these trials are successful and IHL-42X is approved for the market, Procaps will also make IHL-42X for patients.

article thumbnail

Peter Reynolds Article: The Desperate Rearguard Action the British Medical Establishment is Fighting Against Cannabis

Cannabis Law Report

In his written submission to the Health and Social Care Committee , O’Callaghan had the audacity to attack Professor Mike Barnes, based on a scurrilous article in the tabloid Mail on Sunday, for his “significant financial interests in the cannabis industry”. Read full article: [link].

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. View original article. The post Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD appeared first on SpeedWeed.

article thumbnail

Microdose Article: Which Psychedelic Medicine Companies Have the Best Financials?

Cannabis Law Report

However, a company may be in possession of the most healing psychedelic compound in the world, but unless they can prove it through the clinical trial process, their superior medicine will mean little. Yes, of course, it matters greatly who has the most effective medical psychedelic molecule in specific circumstances.

article thumbnail

Article: The Psychedelics Industry in 2022 Was a Wild Ride

Cannabis Law Report

Here’s Psychedelics Spotlight’s round-up of 2022 The Intro Today, with progress being made on legislative fronts, multiple clinical trials inching closer to FDA approval, and people simply letting go of the misconceptions and fear they’ve felt towards psychedelics, we find ourselves in a situation where the impossible doesn’t feel so impossible (..)

article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. However, that does not mean that the path to patents is closed off.

article thumbnail

Article – Stat News: Latest psilocybin patent highlights the swirling battle over psychedelics intellectual property

Cannabis Law Report

patent, but its first for a form of psilocybin the company isn’t using in its clinical trials on treatment-resistant depression. Read full article [link]. This is Compass Pathways’ fourth U.S. As always we’re expecting challenges,” said Compass’s co-founder and president Lars Christian Wilde. “We